Eptinezumab for Migraine Prevention in Patients 50 Years or Older: A Subgroup Analysis of PROMISE-1 and PROMISE-2

被引：0
|
作者：
Martin, V. [1 ]
Tassorelli, C. [2 ]
Ettrup, A. [3 ]
Hirman, J. [4 ]
Cady, R. [5 ]
机构：
[1] UC Headache & Facial Pain Ctr, Cincinnati, OH USA
[2] IRCCS C Mondino Fdn, Pavia, Italy
[3] H Lundbeck & Co AS, Copenhagen, Denmark
[4] Pacific Northwest Stat Consulting Inc, Woodinville, WA USA
[5] Lundbeck La Jolla Res Ctr, San Diego, CA USA
来源：
CEPHALALGIA | 2021年 / 41卷 / 1_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P0289
引用
收藏
页码：157 / 157
页数：1
相关论文
共 50 条
  • [31] Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: Subgroup analysis of PROMISE-2
    Diener, Hans-Christoph
    Marmura, Michael J.
    Tepper, Stewart J.
    Cowan, Robert
    Starling, Amaal J.
    Diamond, Merle L.
    Hirman, Joe
    Mehta, Lahar
    Brevig, Thomas
    Sperling, Bjorn
    Cady, Roger
    HEADACHE, 2021, 61 (01): : 125 - 136
  • [32] Eptinezumab Results for the Prevention of Episodic Migraine over One Year in the PROMISE-1 (PRevention of Migraine via Intravenous Eptinezumab Safety and efficacy-1) Trial
    Silberstein, S. D.
    Kudrow, D.
    Saper, J.
    Janelidze, M.
    Smith, T.
    Dodick, D. W.
    Chakhava, G.
    Wilks, K.
    Schaeffler, B.
    Cady, R.
    Hirman, J.
    Smith, J.
    HEADACHE, 2018, 58 (08): : 1298 - 1298
  • [33] Eptinezumab Improved Patient-Reported Outcomes in Patients With Chronic Migraine and Medication-Overuse Headache: Subgroup Analysis of PROMISE-2
    Diener, H.
    Marmura, M.
    Cowan, R. P.
    Diamond, M.
    Tepper, S. J.
    Starling, A. J.
    Hirman, J.
    Mehta, L.
    Sperling, B.
    Brevig, T.
    Brunner, E.
    Cady, R.
    HEADACHE, 2020, 60 : 106 - 107
  • [34] Eptinezumab improved patient-reported outcomes in patients with migraine and medication-overuse headache: Subgroup analysis of the randomized PROMISE-2 trial
    Starling, Amaal J.
    Cowan, Robert P.
    Buse, Dawn C.
    Diener, Hans-Christoph
    Marmura, Michael J.
    Hirman, Joe
    Brevig, Thomas
    Cady, Roger
    HEADACHE, 2023, 63 (02): : 264 - 274
  • [35] Eptinezumab for Prevention of Chronic migraine: Results of 2 Infusions in the Phase 3 PROMISE-2 (Prevention of Migraine via Intravenous Eptinezumab Safety and Efficacy-2) Trial
    Kudrow, David
    Lipton, Richard
    Silberstein, Stephen
    Cady, Roger
    Schaeffler, Barbara
    Biondi, David
    Smith, Jeff
    NEUROLOGY, 2019, 92 (15)
  • [36] EPTINEZUMAB RESULTS FOR THE PREVENTION OF EPISODIC MIGRAINE THROUGH 1 YEAR IN THE PHASE 3 PROMISE-1 (PREVENTION OF MIGRAINE VIA INTRAVENOUS EPTINEZUMAB SAFETY AND EFFICACY-1) TRIAL
    Dodick, D.
    Janelidze, M.
    Saper, J.
    Kudrow, D.
    Chakhava, G.
    Schaeffler, B.
    Cady, R.
    Hirman, J.
    Smith, J.
    CEPHALALGIA, 2018, 38 : 89 - 90
  • [37] EPTINEZUMAB FOR PREVENTION OF CHRONIC MIGRAINE (CM): RESULTS OF 2 INFUSIONS IN THE PHASE 3 PROMISE-2 (PREVENTION OF MIGRAINE VIA INTRAVENOUS EPTINEZUMAB SAFETY AND EFFICACY-2) TRIAL
    Ashina, M.
    Goadsby, P. J.
    Lipton, R. B.
    Azimova, J.
    Winner, P.
    Schaeffler, B.
    Biondi, D.
    Bhattacharya, S.
    Smith, J.
    Cady, R.
    CEPHALALGIA, 2018, 38 : 84 - 85
  • [38] Eptinezumab for the Prevention of Episodic Migraine Through 1 Year: Results from the Phase 3 PROMISE-1 (Prevention of Migraine via Intravenous Eptinezumab Safety and Efficacy-1) Trial
    Saper, Joel
    Wilks, Kerri
    Chakhava, George
    Cady, Roger
    Schaeffler, Barbara
    Biondi, David
    Hirman, Joe
    Smith, Jeff
    NEUROLOGY, 2019, 92 (15)
  • [39] Eptinezumab Achieved Meaningful Reductions in Migraine Activity as Early as Day 1: PROMISE-2 (PRevention of Migraine via Intravenous Eptinezumab Safety and Efficacy-2) Phase 3 Trial in Chronic Migraine
    Kudrow, D.
    Diamond, M.
    McGill, L.
    Cady, R.
    Bhattacharya, S.
    Biondi, D.
    Hirman, J.
    Smith, J.
    HEADACHE, 2018, 58 : 74 - 74
  • [40] Eptinezumab for Prevention of Chronic Migraine (CM): Results of 2 Quarterly Intravenous Infusions in the Phase 3 PROMISE-2 (PRevention of Migraine via Intravenous Eptinezumab Safety and efficacy-2) Trial
    Lipton, R. B.
    Goadsby, P. J.
    Azimova, J.
    Ashina, M.
    Spierings, E. L. H.
    Winner, P. K.
    Schaeffler, B.
    Biondi, D.
    Bhattacharya, S.
    Smith, J.
    Cady, R.
    HEADACHE, 2018, 58 (08): : 1300 - 1300
12345